Tourmaline is a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

background image


February 27, 2024
Tourmaline Bio to Present at Upcoming Investor Conferences
February 1, 2024
Tourmaline Bio to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
January 29, 2024
Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares


November 6, 2023 3:50 PM EST
Guggenheim Healthcare 5th Annual I&I Conference
November 9, 2023 2:25 PM EST
Truist Securities BioPharma Symposium
November 14 - November 15, 2023
Jefferies London Healthcare Conference

Investor Information

Investor Contact

Lee M. Stern

Meru Advisors